Research and Exclusive Option Agreement Sample Contracts

RESEARCH AND EXCLUSIVE OPTION AGREEMENT

Research and Exclusive Option Agreement • March 6th, 2015 • Aveo Pharmaceuticals Inc • Pharmaceutical preparations • New York

• Contract Type
  Research and Exclusive Option Agreement
• Filed
  March 6th, 2015
• Company
  Aveo Pharmaceuticals Inc
• Industry
  Pharmaceutical preparations
• Jurisdiction
  New York

CAMBRIDGE, Mass.—NOV 11, 2014— AVEO Oncology (NASDAQ: AVEO) today announced that it has entered into a research and exclusive option agreement with Ophthotech Corporation, under which it has provided Ophthotech an exclusive license to investigate the potential of AVEO’s small molecule vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor, tivozanib, outside of Asia for the potential treatment of non-oncologic diseases of the eye.